According to a story in the Boston Globe, Johnson & Johnson has appointed Bayer executive Sandra E. Peterson to oversee the company’s troubled consumer health and manufacturing operations.
The move is an attempt by Alex Gorsky, who became CEO of Johnson & Johnson in April, to address a host of quality, legal and ethical problems involving products and sales practices.
Those problems include what the article characterizes as “an eye-popping series of ...
continue reading...
On the first day of trial, Johnson & Johnson settled a lawsuit centering on complaints that its antipsychotic drug Risperdal caused a male plaintiff to grow breasts, Bloomberg reports. The terms of the settlement are confidential.
It was the first of about 130 lawsuits alleging that Risperdal caused young males to grow breasts. An additional 290 allege other personal injuries caused by the drug.
A lawyer for the plaintiff claimed he suffered ...
continue reading...An opinion piece for the Boston Globe points out that public scrutiny and consumer activism is what prompted Johnson & Johnson’s recent decision to phase out questionable chemicals in its full line of products.
The piece applauds that decision, and urges members of the public to keep up that kind of pressure where corporate actions and accountability are concerned.
Johnson & Johnson had already acceded to consumer activists’ demands by saying it ...
continue reading...
The U.S. Food and Drug Administration has agreed to give priority review status to Johnson & Johnson’s application for a new usage of its prostate cancer treatment Zytiga, Reuters reports. That means the drug will be reviewed faster than usual.
The priority review status is granted by the FDA to expedite the review of drugs to treat serious diseases and fill unmet medical needs. It means the drug will be reviewed ...
continue reading...Consumer advocacy group Center for Science in the Public Interest has filed a federal lawsuit over artificial sweetener Splenda Essentials, claiming that Johnson & Johnson subsidiary McNeil Nutritionals is misleading consumers about the product’s supposed health benefits.
In a press release, CSPI says that Splenda Essentials’ marketing is designed to give the false impression that the sweetener confers health benefits, such as helping its users lose weight and avoid disease.
The lawsuit ...
continue reading...Even as Johnson & Johnson is settling previous charges that may cost about $2.2 billion, the government is making new inquiries into allegations that the company used illegal tactics to promote and market its drugs, the Wall Street Journal reports.
According to the Wall Street Journal, the U.S. Justice Department sent J&J’s Janssen Pharmaceuticals unit a letter in April, requesting documents related to the marketing and promotion of the antibiotic Doribax.
In ...
continue reading...
